ESTRO 2024 - Abstract Book

S2917

Interdiscplinary - Other

ESTRO 2024

The EPIC-F is a valid, reliable, and sensitive tool for assessing QOL among patients with prostate cancer. With its transcultural equivalence, EPIC-F can be effectively utilized for clinical studies, treatment, and monitoring among Filipino patients.

Keywords: Prostate cancer, quality of life, validation

References:

1. Wei JT, Dunn RL, Sandler HM, et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 2002;20:557-66.

2. Bacorro W, et al. Development and pilot-testing of the expanded prostate index composite - Filipino version (EPIC-F). Asia Pac J Clin Oncol. 2023 Aug;19(4):517-524.

1554

Poster Discussion

Automated contour quality assurance: Implementation and impact in the TROG18.01 NINJA Clinical Trial

Phillip Chlap 1,2,3 , Hollie Min 1,2,4 , Mark Sidhom 1,3 , Jarad Martin 5,6 , Angela Whitehead 7 , Alisha Moore 7 , Jason Dowling 4,1 , Annette Haworth 8 , Martin A Ebert 9,10,11 , Shalini K Vinod 3,1,2 , Lois Holloway 3,2,1 1 University of New South Wales, South Western Sydney Clinical Campus, Sydney, Australia. 2 Ingham Institute for Applied Medical Research, Medical Physics, Liverpool, Australia. 3 South Western Sydney Local Health District, Liverpool and Macarthur Cancer Therapy Centre, Liverpool, Australia. 4 CSIRO, Australian e-Health Research Centre, Brisbane, Australia. 5 Calvary Mater Newcastle Hospital, Radiation Oncology, Newcastle, Australia. 6 University of Newcastle, School of Medicine and Public Health, Newcastle, Australia. 7 Trans Tasman Radiation Oncology Group, Clinical Trials, Newcastle, Australia. 8 University of Sydney, Institute of Medical Physics, Sydney, Australia. 9 Sir Charles Gairdner Hospital, Radiation Oncology, Perth, Australia. 10 University of Western Australia, Physics, Perth, Australia. 11 University of Wisconsin, Medical Physics, Madison, USA

Purpose/Objective:

Meeting contour quality assurance (CQA) requirements in a clinical trial has been demonstrated to influence patient outcomes and may impact trial outcomes. However, CQA is time and resource intensive, limiting the ability to use it for all patients in all trials. Previous work has demonstrated the development of an automated approach for CQA of the Clinical Target Volume (CTV) within the TROG 18.01 Novel Integration of New prostate radiation therapy schedules with adJuvant Androgen deprivation (NINJA) trial [1]. In this investigation, we sought to assess the feasibility and impact of using this tool within the NINJA clinical trial.

Material/Methods:

The previously developed automated CQA tool was implemented within the NINJA clinical trial workflow with the goal of streamlining workflow and ensuring practical feasibility [2]. To achieve this, the tool was implemented